Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Creteil – page 40

634 clinical trials in Creteil, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Creteil at a glance
634
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

634 trials in Creteil

Open in trial search

Atrial fibrillation

Not recruiting

Study of Rivaroxaban versus standard care in patients with excessive atrial ectopy or short atrial runs who have high risk of blood clots

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Lactose Monohydrate
  • Sponsor:Assistance Publique Hopitaux De Paris

Eosinophilic granulomatosis with polyangiitis

Not recruiting

Study on Mepolizumab and Drug Combination for Patients with Eosinophilic Granulomatosis with Polyangiitis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Assistance Publique Hopitaux De Paris

Sickle cell disease

Not recruiting

Study of Mitapivat for Patients with Sickle Cell Disease and Kidney Disease

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mitapivat
  • Sponsor:Agios Pharmaceuticals Inc.

Diffuse large B-cell lymphoma+1

Not recruiting

Study of Tazemetostat with R-CHOP for Newly Diagnosed Diffuse Large B Cell Lymphoma or High-Risk Follicular Lymphoma Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:LYSARC

Sjogren's syndrome

Not recruiting

Study on the Effectiveness of Human Normal Immunoglobulin for Treating Painful Nerve Damage in Patients with Primary Sjögren's Syndrome

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Cervix carcinoma

Not recruiting

Study on Atezolizumab for Patients with Locally Advanced Cervical Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Institut Gustave Roussy

Bladder cancer

Not recruiting

Study of Atezolizumab with BCG Treatment for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Previously Received BCG

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Atezolizumab
  • Sponsor:Unicancer

Non-small cell lung cancer stage IV+1

Not recruiting

Study of Encorafenib and Binimetinib for Patients with BRAFV600E-Mutant Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Sepsis

Not recruiting

Study of hydrocortisone and fludrocortisone combination versus placebo in adults with sepsis in intensive care unit to determine corticosteroid response

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Betamethasone
  • Sponsor:Assistance Publique Hopitaux De Paris

Non-small cell lung cancer recurrent

Not recruiting

Study of platinum, pemetrexed, atezolizumab and bevacizumab combination in patients with advanced non-small cell lung cancer who have EGFR, ALK or ROS1 mutations and progressed after targeted therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Centre Francois Baclesse

Plasma cell leukaemia

Not recruiting

Study on Daratumumab, Lenalidomide, and Dexamethasone for Patients with Primary Plasma Cell Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Assistance Publique Hopitaux De Paris

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Fianlimab, Cemiplimab, and Chemotherapy in Adults with Resectable Non-Small Cell Lung Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Regeneron Pharmaceuticals Inc.

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Creteil

What the registry says about research in the country

01 Cardiovascular & Metabolic Research

Groundbreaking studies focusing on TTR amyloidosis and heart disease treatments, evaluating novel therapeutic approaches for cardiac conditions. Research includes assessment of innovative medications for chronic kidney disease with hypertension.

  • TTR Amyloidosis Cardiomyopathy
  • Chronic Kidney Disease
  • Hypertension Management
02 Neurological Disorders

Comprehensive research into various neurological conditions, including innovative studies on Huntington's disease biomarkers and treatment approaches for essential tremor and Parkinson's disease.

  • Huntington's Disease Progression
  • Essential Tremor Treatment
  • Parkinson's Disease Management
03 Oncology & Hematology

Advanced clinical trials in blood cancers and solid tumors, including studies of multiple myeloma treatments and novel approaches for non-small cell lung cancer and mesothelioma.

  • Multiple Myeloma Therapies
  • Acute Myeloid Leukemia
  • Lung Cancer Treatment
04 Autoimmune Conditions

Innovative treatments for inflammatory and autoimmune disorders, investigating new therapies for Crohn's disease, ulcerative colitis, and rheumatoid arthritis.

  • Inflammatory Bowel Disease
  • Rheumatoid Arthritis Management
  • Microbiota Transplantation Studies
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.